EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper

Divya Samineni iD, Karthik Venkatakrishnan iD, Ahmed A Othman iD, Yazdi K Pithavala iD, Srinivasu Poondru, Chirag Patel, Pavan Vaddady iD, Wendy Ankrom, Saroja Ramanujan iD, Nageshwar Budha, Michael Wu, Nahor Haddish-Berhane und 9 weitere

Clinical Pharmacology & Therapeutics · 2024-09 · 116 (3) · 531-545

DOI: 10.1002/cpt.3298 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 16.05.2024. Verfasst von Divya Samineni und 20 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Development, Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The landscape of oncology drug development has witnessed remarkable advancements over the last few decades, significantly improving clinical outcomes and quality of life for patients with cancer. Project Optimus, introduced by the U.S. Food and Drug Administration, stands as a groundbreaking endeavor to reform dose selection of oncology drugs, presenting both opportunities and challenges for the field. To address complex dose optimization challenges, an Oncology Dose Optimization IQ Working Group was created to characterize current practices, provide recommendations for improvement, develop a clinical toolkit, and engage Health Authorities. Historically, dose selection for cytotoxic chemotherapeutics has focused on the maximum tolerated dose, a paradigm that is less relevant for targeted therapies and new treatment modalities. A survey conducted by this group gathered insights from member companies regarding industry practices in oncology dose optimization. Given oncology drug development is a complex effort with multidimensional optimization and high failure rates due to lack of clinically relevant efficacy, this Working Group advocates for a case‐by‐case approach to inform the timing, specific quantitative targets, and strategies for dose optimization, depending on factors such as disease characteristics, patient population, mechanism of action, including associated resistance mechanisms, and therapeutic index. This white paper highlights the evolving nature of oncology dose optimization, the impact of Project Optimus, and the need for a tailored and evidence‐based approach to optimize oncology drug dosing regimens effectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDose-Response Relationship, DrugDrug DevelopmentNeoplasmsHumansMaximum Tolerated DoseUnited StatesUnited States Food and Drug Administration

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Genentech, Inc., South San Francisco, California, USA.
  • EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts, USA.
  • Gilead Sciences, Inc., Foster City, California, USA.
  • Pfizer, San Diego, California, USA.
  • Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
  • Bayer, Cambridge, Massachusetts, USA.

ORCID-Profile: Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, Yazdi K Pithavala, Pavan Vaddady, Saroja Ramanujan, Jitendra Kanodia, Vijay V Upreti, Neeraj Gupta

Zitieren

APA

Samineni, D., Venkatakrishnan, K., Othman, A. A., Pithavala, Y. K., Poondru, S., Patel, C., Vaddady, P., Ankrom, W., Ramanujan, S., Budha, N., Wu, M., Haddish-Berhane, N., Fritsch, H., Hussain, A., Kanodia, J., Li, M., Li, M., Melhem, M., Parikh, A., …, & Gupta, N. (2024). Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper. Clinical Pharmacology & Therapeutics, 116(3), 531-545. https://doi.org/10.1002/cpt.3298

Vancouver

Samineni D, Venkatakrishnan K, Othman AA, Pithavala YK, Poondru S, Patel C, et al. Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper. Clinical Pharmacology & Therapeutics. 2024;116(3):531-545. doi:10.1002/cpt.3298

BibTeX
@article{Samineni2024,
  author = {Samineni, Divya and Venkatakrishnan, Karthik and Othman, Ahmed A and Pithavala, Yazdi K and Poondru, Srinivasu and Patel, Chirag and Vaddady, Pavan and Ankrom, Wendy and Ramanujan, Saroja and Budha, Nageshwar and Wu, Michael and Haddish-Berhane, Nahor and Fritsch, Holger and Hussain, Azher and Kanodia, Jitendra and Li, Meng and Li, Mengyao and Melhem, Murad and Parikh, Apurvasena and Upreti, Vijay V and Gupta, Neeraj},
  title = {Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {116},
  number = {3},
  pages = {531--545},
  doi = {10.1002/cpt.3298}
}
Kostenlos starten →